Acrivon has developed its AP3 Interactome, a proprietary, computational analytics platform driven by Generative ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ETTo highlight differentiated drug discovery capabilities with its Generative ...

CHK1 also phosphorylates and activates WEE1 during G2 (centriole maturation), which can phosphorylate and inhibit CDK1 activity. CDK1/Cyclin B interacts with Aurora kinase A to enhance its ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for ...

NEW YORK, February 26, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its ...

Prologis and Microchip Technology are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual ...

X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. Drug ...

(Sharecast News) - Uniphar reported a strong 2024 on Tuesday, recording an 8.5% increase in revenue to €2.77bn and a 9.6% rise in gross profit to €427.6m. The AIM-traded firm said adjusted ...